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Abstract
The popular theory six degrees of separation is used in this review as an analogy to relate all radiosensitization to
oxygen. As the prime mover of all radiosensitizers, the pervasive influence of oxygen has consciously or uncon-
sciously influenced the direction of research and development and provided the benchmark against which all other
compounds and approaches are measured. It is the aim of this review to develop the six degrees of separation
from oxygen analogy as a unifying framework for conceptually organizing the field and for giving context to its varied
subspecializations and theories. Under such a framework, it would become possible for one area to consider ques-
tions and problems found in other areas of radiosensitization, using a common analogy, that would allow for further
development and unification of this multifaceted discipline. In this review, approaches to the development of radio-
sensitizers and the current state of research in this field are discussed, including promising new agents in various
stages of clinical development.
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Introduction
The view that everything is connected to everything else according to
the popular six degrees of separation theory finds corroboration on a
therapeutic level in the field of radiosensitization. Analogous to a phy-
logenetic tree, the evolutionary lineage of radiation sensitizers from
the oxygen radiosensitizers to the hypoxic cytotoxins can be traced
back to a common ancestor—oxygen, the first “true” radiation sensi-
tizer. The tree metaphor not only offers a way to keep track of the
features of different radiosensitizers but also provides a framework
for conceptualizing diverse mechanistic approaches. In this review,
we outline the approaches to the development of radiosensitizers
and discuss the current state of research.
As solid tumor growth outstrips the ability of the surrounding
vasculature to supply blood and nutrients to the new cells, the tumor
cell mass becomes increasingly heterogeneous, with microscopic and
macroscopic areas of necrosis surrounded by cells that have very low
oxygenation levels. Under normal circumstances, tumor cells would
undergo apoptosis, mainly through the p53 pathway; however, these
more aggressive, hypoxic cells adapt to the low oxygen levels by ac-
tivation of a number of genes, including the hypoxia-inducible factor
(HIF) pathway. HIF-1α, in particular, is associated with the induc-
tion of vascular endothelial growth factor (VEGF) and factors regu-
lating glucose transport and glycolysis such as GLUT-1 and GLUT-3
[1], enabling the tumor to independently build vasculature and to
support metabolic pathways. The ability of more aggressive cancer
cells to survive hypoxic conditions leads to selection against apoptosis
and an increased resistance to chemotherapy, as well as a propensity
to metastasize. Indeed, tumor hypoxia itself [2], as well as elevated lev-
els of HIF-1α [3], has been linked to poor treatment success charac-
terized by drug resistance, cancer recurrence, and poor survival rates.
The low oxygen levels in tumors are also associated with a poor re-
sponse to radiotherapy [4]. For example, nearly 40% of breast cancers
have hypoxic regions with oxygen concentrations below that required
for half-maximal radiosensitivity [5].
Well-oxygenated cells show enhanced radiosensitization compared
to hypoxic cells. This oxygen enhancement ratio typically ranges be-
tween 2.5 and 3.0 [6]. Oxygen enhancement ratio is described as the
relative sensitivity of oxic cells/anoxic cells to the lethal effects of low
linear-energy-transfer (LET) radiation: As the level of oxygen increases,
so does the sensitivity of cells to radiation. Through its unique electronic
configuration, oxygen, the definitive blueprint for radiosensitizers,
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promotes free radical formation. As the most electron-affinic cellular
molecule, it is readily reduced by electrons formed from the incident
radiation. On irradiation of oxygenated tumors, energy transfer results
in the radiolysis of water with the initial formation of an ion radical that
then forms the highly reactive hydroxyl radical after reaction with an-
other water molecule. The presence of oxygen leads to the formation of
peroxide after reaction with the hydroxyl radical. Formation of peroxide
results in “fixation” or permanent cellular and DNA damage. For this
reason, oxygen is the definitive hypoxic cell sensitizer and its primacy in
radiation sensitization is referred to the “oxygen effect.”
In the absence of oxygen, peroxide is not formed and the sulfhydryl-
containing groups such as cysteine and glutathione can restore or recon-
stitute DNA through hydrogen donation. As a result, hypoxia, endemic
to most solid cancers, can lead to radioresistance both through increased
free radical scavenging and through changes in the pattern of gene
expression (e.g., induced by upregulation of the transcription factor,
HIF-1α), which alters the malignant potential of tumors leading to more
aggressive survival traits and resistance to radiation and chemotherapy.
The oxygen effect has driven the evolution of radiosensitization
from initial attempts to increase the oxygenation of tumors with hyper-
baric gases to the use of increasingly sophisticated, targeted approaches
that take advantage of physiological differences in PO2 between tumors
and healthy tissue.
Radiosensitizers evolved from the same common ancestor—oxygen;
as a result, however different their mechanisms of action, they are
interrelated through the common thread of their dependence on (or in-
dependence from) the oxygen effect. Thus, understanding the mecha-
nism of action of a radiosensitizer amounts to understanding where on
the phylogenetic tree a compound’s traits exist. Mechanistic categories
of radiosensitizers are described below.
Increasing Oxygen Delivery to the Tumor:
Oxygen Radiosensitizers
1. Hyperbaric oxygen
2. ARCON
3. RSR-13
4. Erythropoietin
5. Blood transfusions
6. Oxyrens
7. Local oxygenation
The age of radiosensitization was ushered in by the pioneering work
of Thomlinson and Gray [7] demonstrating that the sensitivity of
tumor cells to radiation damage depended on the presence of oxygen
in the tumor microenvironment. This seminal discovery, describing
diffusion-limited hypoxia, paved the way for the development of radio-
sensitizers that attempted to increase the oxygen content of tumors.
Based on this model in which oxygen delivery is compromised by lim-
ited diffusion inside tumors, early approaches to improve oxygen status
of tumors involved administration of hyperbaric oxygen (HBO) [8].
However, although breathing oxygen during radiotherapy had limited
success in head and neck and cervical cancers, there was no benefit in
other cancers such as the CNS, bladder, and skin.Moreover, the admin-
istration of HBO has proved cumbersome and has also resulted in seri-
ous adverse effects from oxygen toxicity in clinical application. Interest
in this approach has, therefore, waned significantly.
Whereas exposure to HBO and carbogen (i.e., 95% oxygen/5%
carbon dioxide) increases the oxygen diffusion distance, thereby reduc-
ing chronic hypoxia, these modalities do not address acute hypoxia re-
sulting from inadequate blood flow in tumors or anemic hypoxia which
may be tumor-associated or treatment-related. The failure of HBO or
carbogen as radiosensitizers may be due, therefore, to their failure to
correct these other causes of tumor hypoxia.
The need to address acute, as well as chronic hypoxia, led to the
investigation of ARCON (Accelerated Radiotherapy, Carbogen, and
Nicotinamide) [9,10], a mixed modality approach, to attempt to over-
come tumor proliferation and reverse chronic and acute hypoxia, re-
spectively. Nicotinamide, a vasodilator, was included in the regimen
to increase tumor blood flow to increase tumor PO2. However, results
in squamous cell carcinoma of the head and neck were mixed, with
benefit reported in laryngeal tumors but not in oral cavity and oropha-
ryngeal tumors [10].
Other direct-line descendants of the increased tumor oxygenation
approach include the use of blood transfusions and dosing of eryth-
ropoietin to increase hemoglobin concentration. However, correction
of anemia with blood transfusions or erythropoietin has, in some
cases, shown a decrement in patient survival and is an area of recent
controversy [11,12]. An alternative approach involves increasing tumor
oxygen using hemoglobin-affecting drugs dubbed Oxyrens or oxygen
release enhancers. Efaproxiral (RSR-13) is a synthetic allosteric modifier
of hemoglobin that decreases hemoglobin-oxygen binding capacity,
thereby enabling greater oxygen delivery to tissues. However, results
from ongoing trials with this drug have had limited success. In partic-
ular, although Efaproxiral was well tolerated and shown to increase
oxygen delivery, the ENRICH trial in patients with breast cancer meta-
static to the brain did not demonstrate a radiosensitizing effect [13],
and currently, there are no ongoing, actively recruiting clinical trials
with this drug. Myo-inositol trispyrophosphate or OXY111A is a novel
allosteric modulator of oxygen affinity to hemoglobin that has been
shown to enhance delivery of oxygen to hypoxic tissues in preclinical
studies resulting in the lower expression of HIF-1α and VEGF with
concomitant reduced angiogenesis compared to control [14,15]. Al-
though no clinical or preclinical studies have described the activity of a
combination of this drug with radiation, the development of OXY111A
is still at an early stage with the compound currently in phase 1.
Using a different, but direct approach that is particularly applicable
to nonresectable tumors, Ogawa et al. developed a radiosensitizing
treatment that directly oxygenated the tumor through intratumoral
administration of hydrogen peroxide either alone [16] or with a per-
oxidase inhibitor in the form of hyaluronic acid [17]. In a phase 1 trial,
Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas, type II
(KORTUC II) was found to be well tolerated with adverse effects lim-
ited to mild local pain, with 9 of 11 patients demonstrating a complete
response by RECIST criteria [18].
Oxygen Mimetics/Electron-Affinity Agents
1. Nitroimidazoles
2. Transition metal complexes
3. Nitric oxide
The development of “oxygen mimetics,” using the chemical prop-
erties of molecular oxygen as a template, feature compounds with
high electron affinities and better diffusion properties into anoxic tissue.
Unlike oxygen, which is rapidly consumed by respiring cells, these
agents are less rapidly metabolized by tumors, enabling better diffusion
and penetration into hypoxic regions. These compounds are described
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as “true radiosensitizers” in that they can theoretically substitute for
oxygen in “fixing” radiation-induced damage of DNA, making it non-
repairable and hence lethal. They represent the first evolutionary branch
off the main trunk in the development of potential radiosensitizers.
The most well studied and representative class of oxygen mimetics
is that of the nitroimidazoles, which undergo enzymatic and radiation-
induced redox reactions. These agents have no intrinsic activity; their
effect only becomes evident in the presence of ionizing radiation to “fix”
or stabilize DNA radical lesions in an oxygen-deficient cell. In preclin-
ical studies, the 2-nitroimidazole, misonidazole, had a higher electron
affinity and was more effective than the 5-nitro imidazole, metronida-
zole (Flagyl), resulting in significant sensitization of tumors to radiation
without concomitant effects in normal tissues [19–21]. In hypoxic
tumor cells, nitroimidazoles undergo a series of enzymatic reductions,
mediated by nitroreductase enzymes expressed under hypoxic condi-
tions, leading to the generation of highly reactive anion radicals, which
then irreversibly bind to cellular components.
In clinical trials, however, misonidazole caused severe peripheral
and central neuropathy, which precluded safe and efficacious use
in combination with radiotherapy. Notably, at clinically tolerable doses,
misonidazole was ineffective as a radiosensitizer [22]. Interestingly, the
less electron-affinic 5-subsituted nitroimidazole, metronidazole, did not
cause the same level of neuropathy but was an inferior radiosensitizer.
Although neurotoxicity associated with nitroimidazole therapy is not
fully understood, this effect has been attributed to a redox reaction of
catecholamine and serotonin neurotransmitters with the nitroimida-
zoles leading to the oxidative formation of neurotoxic semiquinone
radicals [23,24]. An alternative hypothesis suggests that the generation
of highly reactive nitro anion radicals is responsible for “axonal swelling
with increased water retention” [25]. This alternative hypothesis was
supported by data from less lipophilic analogs, including the nitrotria-
zole, Sanazole, that were found to be less neurotoxic [26]. Second-
generation nitroimidazole radiosensitizers (e.g., nimorazole, etanidazole)
were designed to increase hydrophilicity and thereby minimize expo-
sure to neural tissues. Of these, etanidazole, had the best preclinical
toxicity and efficacy profile but, unfortunately, did not afford any
global benefit for patients of head and neck cancers in randomized
studies [27].
Nitrogen oxides and nitric oxide, in particular, act as radiosensitizers
through many different mechanisms and by direct and indirect means.
Although nitric oxide as a radiosensitizer is described in more detail
below, it is important to note that one mechanism of its action is in
“fixing” radiation-induced damage to cellular molecules, in an analo-
gous way to oxygen.
Transition Metal Complexes
1. Platinum analogs
2. Motexafin gadolinium
Mimicking the redox systems of the nitroimidazoles, the chemistry
of transition metal complexes has been exploited for use in radio-
sensitization. By far, the most successful and best-known clinical ex-
ample of a metal complex, which enhances the effect of radiation in
hypoxic cells, is the cytotoxic drug, cisplatin. Several possible mech-
anisms by which platinum complexes (cisplatin, oxaliplatin, and car-
boplatin) sensitize tumors to radiation have been described, including
inhibition of DNA repair [28]. However, like the nitroimidazoles,
they also have the potential to form radicals by accepting hydrated
electrons generated by ionizing radiation and “fix” radiation damage.
Importantly, these agents are not selective and therefore possess sig-
nificant normal tissue toxicity arising from the metal-mediated gener-
ation of the hydroxyl radical through the Fenton reaction [28].
In contrast to cisplatin, radiosensitizers based on lanthanide (III)
complexes have little or no intrinsic activity but undergo futile redox
cycling [29,30]: In the 3+ oxidation state, the metal complexes have
high electron affinity allowing ready electron transfer between the
metal and other cellular substrates such as DNA, water, oxygen,
and intracellular reducing agents [31]. The subsequent catalytic trans-
fer of the electron to oxygen not only produces reactive species like
hydrogen peroxide that lead to oxidative damage by direct attack of
biological macromolecules but also regenerates the initial parent com-
pound in an unchanged form. The cycle repeats itself and can poten-
tially deplete the cell of the reservoir of its cytoprotective agents and
energy. This catalytic behavior has been termed futile redox cycling and
is ultimately toxic to cells by inhibiting cellular repair [22].
Gadolinium porphyrin complexes, composed of the lanthanide
coordinated to a porphyrin (motexafin gadolinium, MGd, Xcytrin
or Gd(III)-tex), have been investigated as potential radiosensitizers
[32–34]. In vitro studies suggest that gadolinium is able to deplete
ascorbate and glutathione by direct binding, leading to a consequent
increase in free radical production with improved radiosensitivity [35].
Although, preclinically, this radiosensitization effect was not uniform
over different tumor types [36], clinical development demonstrated a
benefit to patients [34]. In a phase 1 study, MRI showed a passive ac-
cumulation of the drug in tumor cells, presumably by extravasation
from leaky vessels [32,34]. In a phase 3 study, patients with non–small
cell lung cancer (NSCLC) brain metastases when treated with whole
brain RT and Xcytrin experienced a significantly prolonged interval
to neurological progression compared to patients treated with RT alone
[37]. In 2007, Pharmacyclics received a nonapprovable letter from the
US Food and Drug Administration for Xcytrin, and no further devel-
opment has been reported.
Hypoxic Cytotoxins (HACs)
1. Mitomycin, porfiromycin, and apaziquone
2. Tirapazamine
3. AQ4N
Like a family tree, the radiosensitizer evolutionary branches diverge
in an entirely different direction with hypoxic cytotoxins. These clas-
ses of compounds attempt to exploit, rather than overcome, tumor
hypoxia. The drawbacks of tumor reoxygenation and the oxygen mi-
metics led to an interest in research on hypoxia-selective agents that
had independent cytotoxic activity in addition to radiosensitization.
These hypoxia-activated cytotoxins (HACs) were developed based
on the hypothesis that the differences in oxygenation between normal
and malignant cells can be turned from a prognostic handicap into a
clinical advantage [2,38]. Conceptually, compounds that are con-
verted to cytotoxic agents under different oxygenation states should
be effective radiosensitizers. For all of these compounds, because ac-
tivation occurs rapidly, a balance of key parameters was found to be
critical for effective antitumor activity. Of these the reduction poten-
tial [39,40], a factor that influences the ratio of activity under hypoxic
versus normoxic conditions, the relative expression of the relevant re-
ductases in tumor versus normal tissue [41], and tumor penetration
[42] have proven to be most important [43].
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Mitomycin, Porfiromycin, Apaziquone
Mitomycin C (MMC) is the prototype radiosensitizing natural
product cytotoxin that undergoes enzymatic reduction to generate
an alkylating species; however, it has severe adverse effects attributed
to its lack of preferential selectivity for hypoxic cells and, in most
clinical trials, was only administered once or twice during a radio-
therapy course [44]. Although it is no longer widely used clinically,
MMC did demonstrate the potential of bioreductively activated drugs
to selectively kill hypoxic cells in solid tumors [45]. The molecular
mechanism of MMC, bioactivation through CYP 450 reductive me-
tabolism, followed by a N-alkylation [46], represents a model for
HAC. These include Porfiromycin (methyl mitomycin) [47], a close
analog of MMC that has an improved therapeutic index compared
to MMC. The combination of radiotherapy and Porfiromycin has been
studied both preclinically [47–49] and in a number of long-term trials
in patients with squamous cell cancer of the head comparing the effect
of radiotherapy with either Porfiromycin or MMC [50,51]. Despite
promising preclinical data, Porfiromycin was found not be as effective
as MMC when combined with radiotherapy for the treatment of this
tumor type [50].
Structurally similar to MMC, apaziquone (EOquin, EO9) is a bio-
reductive cytotoxic agent that retains the indolequinone functionality
required for activity [52]. Apaziquone undergoes an oxygen depen-
dent one electron reduction, mediated by NQO1 (NAD(P)H: Quinone
oxidoreductase, EC 1.6.99.2) [53] to give a radical species with cytotoxic
activity through DNA double-strand breaks. Although NQO1 is the pri-
mary activation catalyst for this drug, activity under hypoxic conditions
has been reported in those tumors that have low or no levels of NQO1.
Under these conditions, activation of apaziquone is catalyzed by single-
electron reductases, for example, CYP450s. In addition, the drug also
undergoes an oxygen-independent two electron reduction by DT diaph-
orase [54,55]. In early clinical studies of the drug administered IV, how-
ever, poor pharmacokinetic properties, especially rapid clearance and
poor tumor penetration as well as an unfavorable toxicity profile, resulted
in a reexamination of the route of delivery [56]. Apaziquone is now being
developed for superficial bladder cancer and is being administered intra-
vesically [52,57–59].
Tirapazamine
Originally identified as a herbicidal agent, the nitroxide tirapazamine
(TPZ) was first described as a potential anticancer agent in 1986 [60].
The chemical structure of this compound incorporates a 1,2,4-
benzotriazine-1,4 dioxide group that is susceptible to bioreduction.
TPZ differs from the oxygen mimetics in that it does not “fix” radiation-
induced DNA damage, but like the HAPs and HACs, is preferentially
cytotoxic under hypoxic conditions. Unlike other HAPs and HACs,
however, bioreduction results in the generation of a cytotoxic radical
that exerts its effects directly on the surrounding tissue. In a form of
futile cycling, TPZ undergoes reversible, one-electron reduction to
form a neutral radical intermediate under aerobic conditions. Under
hypoxic conditions, this radical is stabilized and can act as a cytotoxic
agent in its own right [61]. Further hemolytic cleavage results in the
expulsion of a hydroxyl radical, a known DNA-damaging species [40].
TPZ was found to markedly increase radiation-induced cell death
in a dose- and schedule-dependent manner, particularly in hypoxic
tumors [62]. Promising results were obtained in various preclinical
studies and early-phase clinical trials in lung cancer, cervical cancer,
ovarian cancer, melanoma, and head and neck cancer, with specific
synergy being seen between TPZ and fractionated radiation and
platinum-based chemotherapy. However, despite these encouraging
results, several phase 3 trials failed to demonstrate any benefit in re-
sponse rate, overall survival, or progression-free survival of adding
TPZ to chemotherapy or radiation therapy in NSCLC or head and
neck cancer. A recent review describes the key clinical studies in the
development of TPZ [63]. Research into TPZ is now focused on the
identification of the specific characteristics that resulted in the ob-
served narrow therapeutic window and designing improved analogs.
Preliminary results suggest that, once activated, TPZ reacts very
quickly. A consequence of these kinetics is that cytotoxic activity oc-
curs in a small area of cells that have the requisite level of hypoxia for
activation, with little cell killing, or poor bystander effect, beyond this
region. In addition, TPZ has been shown to have poor tumor pene-
tration properties that may arise from not just poor physicochemical
properties but also from vascular disrupting activity that increases tu-
mor hypoxia and restricts tumor penetration further [64]. Analogs
with improved physicochemical properties are the subject of current
research [65–67]; however, the future of TPZ itself is uncertain and
may depend on the ability to select those patients who have tumors
that are profoundly hypoxic.
AQ4N
Exploiting the observation that N-oxides are nontoxic metabolites
of tertiary amine drugs, AQ4N (banoxantrone) was designed to have
antitumor activity once it was reduced from a benign, fully oxidized
species, with little intrinsic activity, by CYP450 enzymes, particularly
CYP3A [68–70]. The high polarity of the di-N-oxide functional groups
on the side chains prevented entry into cell nuclei and DNA binding,
contributing to the very low intrinsic activity of the fully oxidized de-
rivative [69]. AQ4N was also designed to release a stable and persistent
cytotoxin, AQ4 a potent DNA intercalator and topoisomerase II
poison [70], similar in structure to mitoxantrone, that would, potentially,
have a greater bystander effect. This feature was to circumvent the
drawback of TPZ and analogs that are activated and consumed in areas
of specific hypoxia. In preclinical models, AQ4N enhanced the effect of
radiation in an additive manner, independent of the schedule of dosing
with respect to radiation [71–73]. AQ4N has been investigated in the
clinic as a single agent and in combination with radiation and temozo-
lomide. Although single-agent trials were promising [74–76], with
AQ4N exhibiting accumulation in the tumor, low overall toxicity
and some partial responses in patients, results from combination trials
with radiation have not been reported to date and no new studies
are planned.
Direct Targeting of Hypoxia-Related Molecules
1. HIF-1α
2. Inhibitor of apoptosis (IAP) proteins, Survivin and XIAP
HIF-1α is the central transcriptional mediator of the hypoxic re-
sponse in tumor cells and its overexpression is associated with in-
creased angiogenesis, radioresistance, and a clinically poor prognosis
in a variety of malignant tumors [77]. Therefore, HIF-1α and related
proteins may serve as a radiotherapeutic target. Although there are no
anticancer drugs that explicitly target HIF-1α, there are a surprising
number of approved and experimental drugs that decrease levels of
HIF-1α. These fall into a wide category of mechanisms that include
antibodies against HER2, topoisomerase inhibitors, inhibitors of
DNA activation through HDAC, and HSP90 inhibitors [78–80].
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Several novel small molecule inhibitors of HIF-1α are now in early
clinical trials. PX-478, an orally administered compound with radio-
sensitizing properties, derived from the clinical alkylating agent
melphalan [81], is an inhibitor of HIF-1α expression [81–83]. In a
phase 1 trial of PX-478 [84], 35% of patients achieved a stable dis-
ease response along with dose-proportional inhibition of HIF-1α
levels. Interestingly, because PX-478 differs chemically from melpha-
lan solely through oxidation to an N-oxide functionality, by analogy
with the N-oxide AQ4N, PX-478 could also be considered as a
hypoxia-activated cytotoxic agent. Nevertheless, data to date describe
the activity of PX-478 as being linked to changes in HIF-1α signaling
after irradiation, suggesting a mechanism independent of melphalan-
like effects [85,86]. However, the association with melphalan, which
does not have radiosensitizing properties, diminishes the attractiveness
for the development of PX-478 in combination with radiation.
Phase 1 clinical trials with EZN-2968, an antisense oligonucleo-
tide inhibitor of HIF-1α expression, demonstrated safety and poten-
tial activity in one patient with metastatic renal cell carcinoma [80].
The expression of HIF-1α is closely correlated with the expression
of a family of proteins , the inhibitors of apoptosis (IAP) that regulate
cell death [87]. Of these, survivin and XIAP [88,89] are upregulated
in malignant tissue, but not in normal tissue, making them attractive
therapeutic targets. Inactivation of these IAPs using antisense oligo-
nucleotides has resulted in radiosensitization [90] as well as chemo-
sensitization effects [91,92]. In addition, a survivin-based vaccination
phase 1 study in oral cancer patients demonstrated that the peptide
vaccination with survivin-based peptides was safe and had some ther-
apeutic potential [93]. Further clinical trials, including a study in
adult anaplastic glioma, are in progress [94].
Reduction of HIF-1α corresponds to a change in tumor oxygen
response. Consequently, there are many compounds that are not nec-
essarily regarded as HIF-1α inhibitors but nevertheless influence trans-
lation, expression, transcription, degradation, or clearance of HIF-1α,
acting on different molecular targets. In addition to those described
above, these include aminoflavone, digoxin, and hsp90 and HDAC in-
hibitors [80]. Although molecules that reduce HIF-1α levels have a
clear potential to act as effective hypoxic radiosensitizers, data on com-
bination therapy are mostly limited to the preclinical stage, and none of
these compounds are currently being developed as radiosensitizers.
Hypoxia and/or Radiation-Activated Prodrugs
of Cytotoxins (HAPs)
1. TH-302
2. PR-104
As offshoots of hypoxic cytotoxins, the hypoxia-activated prodrugs
were designed to exploit tumor hypoxia, incorporating specific func-
tional groups in their structure that can be bioreduced under hypoxia
or after irradiation to release known cytotoxic agents. Unlike hypoxic
cytotoxins, the hypoxia-activated prodrugs possess a significant by-
stander effect: These agents release a cytotoxic species with an appre-
ciable half-life that can diffuse into tumors and exert a pronounced
cell-killing effect away from the zone of activation.
For example, TH-302 [95–97], currently in phase 2 clinical trials,
contains a 2-nitroimidazole functionality that serves as a hypoxic trigger
releasing an achiral phosphoramidate cytotoxin, related in structure to
ifosfamide. Although the alkylating nature of the TH-302 ifosfamide-
like “warhead” would be expected to predominantly account for a
radiosensitizing effect, it could be expected that the nitroimidazole
functionality may also contribute to the effect at sufficiently elevated
doses. Although preclinical studies have shown radiation sensitivity
enhancement of tumor cells [98], no clinical studies of TH-302 as a
potential radiosensitizer have been initiated.
Activation under deep hypoxia by nitroreductases has been ex-
ploited through the development of nitrobenzamide mustards, as
exemplified by the prototypical compound, SN 23862. The nitro-
benzamides exploit the metabolic switch from electron withdrawing
to donating functional group interconversion; bioreduction of nitro to
hydroxylamino and amino, to activate DNA cross-linking cytotoxins.
Of the many nitrobenzamides studied, PR-104 is a water-soluble dou-
ble prodrug that is hydrolyzed by systemic phosphatases to a lipophilic
intermediate (PR-104A) that is able to diffuse to and from the hypoxic
activation zone inside the tumor mass. Although hypoxic bioreduction
activates a cytotoxic nitrogen mustard-alkylating agent, PR-104 can
also be activated by aldo-keto reductase independent of hypoxia [99],
suggesting that there would be additional cytotoxicity under normoxic
conditions. In an in vitro preclinical study comparing the oxygen de-
pendence and tissue transport properties of PR-104A with tirapaza-
mine, performed in the context of predicting antitumor activity in
combination with radiation, Hicks et al. [100] confirmed that PR-
104 had different PK/PD characteristics compared to tirapazamine
and was significantly more cytotoxic when combined with radiation
in mouse xenograft models. These marked differences were attributed
to a bystander effect resulting from diffusion of active metabolites away
from severely hypoxic zones. Although a phase 1 study was completed
[101], a phase 2 trial in NSCLC with docetaxel did not demonstrate
sufficient efficacy for further development. In addition, the combina-
tion of PR-104 and sorafenib in hepatocellular carcinoma was not well
tolerated, resulting in the termination of the trial. Current development
of PR-104 is focused on AML [102].
Nitric Oxide
1. NO donors
2. TSP-1/CD47
3. VEGF
Is there another endogenous molecule or molecules that can not
only mimic but possibly improve on the effects of oxygen as a radio-
sensitizer? The answer is nitric oxide (NO). Similar to the oxidative
stress induced by oxygen, nitric oxide or NO can “fix” or stabilize
damage to critical cellular/molecular species through nitrosative stress
pathways. Studies on the role of the endogenous vasodilator, nitric
oxide in cancer suggest a number of different and contradictory roles
for this ubiquitous molecule, depending on its concentration, the la-
tency of effect and the cell type. Oxidative and nitrosative stress path-
ways involve the generation of reactive species such as peroxynitrite
(ONOO−), nitrous acid, and nitric acid that are directly and indi-
rectly cytotoxic through mechanisms that include DNA cross-linking
[103], glutathione depletion [104], protein nitrosylation [105], and
inhibition of mitochondrial respiration [106].
Nitric oxide is generated endogenously by nitric oxide synthase in
mammals through the oxidation of L-arginine [107]. As an uncharged
free radical, nitric oxide freely diffuses across cell membranes and is
able to bind to soluble guanylate cyclase (sGC), its most sensitive known
target, to induce the production of cyclic GMP, thereby regulating vas-
cular physiology.
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The applicability of nitric oxide donors in a clinical oncology setting
is controversial. NO at low concentrations is antiapoptotic and pro-
angiogenic whereas, at higher levels, is proapoptotic through activation
of downstream signaling pathways or after conversion to other reactive
nitrogen species [108,109]. Accordingly, some studies have demon-
strated improved tumor oxygenation and blood flow linked with radio-
sensitization resulting in tumor shrinkage, whereas other studies have
reported the opposite, that is, decreased blood flow with increased rate
of tumor growth, presumably linked to the expression of hypoxia-
mediated transcription factors [110]. Nevertheless, more recent reports
have demonstrated a radiation and chemosensitizing effect of low con-
centrations of nitric oxide, delivered as an NO patch or by a donor
molecule [111–113].
These apparently contradictory results could also be attributed to
the heterogeneous vasoresponsive capacity of tumor vessels depend-
ing on the presence or absence of smooth muscle cells and the struc-
tural relationship between vascular beds of the tumor relative to
surrounding normal tissues, resulting in blood flow redistribution
through steal or antisteal effects [114]. The presence of nitric oxide
has also been established in conjunction with the oxygen mimetics,
in that 5-nitroimidazoles [115] and sanazole [116] have been reported
to release nitric oxide.
In a phase 1 study of NSCLC patients [117], tumor shrinkage and
decreased blood flow was associated with administration of the nitric
oxide synthase inhibitor, N -nitro-L-arginine (L-NNA) as assessed by
dynamic contrast-enhanced computed tomography. The extrapola-
tion from these data would suggest that NO donation increases tumor
perfusion and therefore tumor growth. However, in a phase 2 study,
prostate cancer patients who had failed primary therapy [118] were
treated with low-dose sustained delivery of glyceryl trinitrate resulting
in a significant decrease in prostate-specific antigen. The authors sug-
gested that, although low-dose NO had no direct cytotoxic effect, NO
decreased the emergence of a more malignant phenotype, including
invasion and metastases, presumably by decreasing tumor hypoxia
through improved tumor blood flow.
In contrast to directly modulating NO levels, thrombospondin 1
(TSP-1), acting through its receptor CD-47, mediates NO inhibition
and antiangiogenesis. TSP-1 dysregulation has been observed in a
number of human and murine tumors [119]. TSP-1 expression is
frequently suppressed in tumors, preventing nitric oxide antagonism
and thereby promoting NO proangiogenic effects. However, increased
circulating TSP-1 levels derived from nontumorigenic stromal cells
have been reported. Whereas local NO production drives tumor angio-
genesis, systemic NO-mediated vasodilation preferentially enhances
normal tissue perfusion at the expense of the tumor, similar to the
steal effect. The known ability of endogenous TSP-1 to vasoconstrict
and limit NO-driven responses in normal tissue increases tumor per-
fusion by decreasing circulation to healthy tissues [119]. Therapeutic
concepts to modulate the TSP-1/CD47 interaction have been de-
scribed in the literature [120] but have not yet advanced into for-
mal development.
In contrast to these nonclinical experimental therapeutic modali-
ties, bevacizumab [121], etaracizumab, sorafenib, and sunitinib are
US Food and Drug Administration–approved drugs that have dem-
onstrated clinical efficacy in oncology and act specifically, or in part,
by blocking the VEGF pathway. In angiogenesis, VEGF stimulates
endothelial nitric oxide release, whereas NO negatively feeds back on
VEGF action [121]. This precise regulation maintains vascular homeo-
stasis. In cancer, dysregulation occurs when VEGF, driven by tumor
hypoxia, is overexpressed, leading to excessive endothelial cell prolifer-
ation and neovascularization.
Although literature describing the radiosensitizing properties of
nitric oxide is extensive, nitric oxide has also been described as a radio-
protectant. This seemingly contradictory behavior could [122] be
attributed to NO concentration gradients with low doses resulting
in cell survival signaling and high doses likely participating in the gen-
eration of free radicals, resulting in direct cytotoxicity and in the fix-
ation of radiation-induced radical damage. Liebmann et al. [123]
demonstrated that pretreatment with nitric oxide donors enhanced
the survival of mice to whole body irradiation. RRx-001, a nonexplo-
sive pernitro compound possessing a novel pharmacophore and which
originated in the defense industry has been tested in animal models
of radiosensitization and radioprotection. In preclinical models, pre-
liminary data suggested that RRx-001 protected intestinal crypt cells
against the effects of irradiation while significantly radiosensitizing
SCCVII and RIF-1 syngeneic tumor models [124]. In a related ap-
proach, Maxhimer et al. [125] reported radioprotection of soft tissue
and prevention of apoptosis in irradiated muscle in vivo by suppression
of CD-47 expression, although it is possible that the mechanism could
be NO-independent.
Conclusions
In this review, we have proposed a phylogenetic tree as a metaphor
for the interrelatedness between different classes of radiosensitizers
with disparate mechanisms of actions. Radiosensitization approaches,
starting from molecular oxygen, as the common ancestor, initially
focused on mimicking oxygen’s unique properties, first by increasing
intratumoral oxygen concentration and then by mimicking its elec-
tron affinity to fix the effects of radical damage (Figure 1).
With the relative lack of success of these approaches, the develop-
ment of radiosensitizers turned toward exploitation of tumor hypoxia.
In this logical branching point, hypoxia became a therapeutic disad-
vantage that could be harnessed and used to kill tumor cells, turning
the hypoxia problem into an opportunity.
Although the promise of first in class compounds like mitomycin C
and misonidazole was never fully realized, subsequent generations of
radiosensitizers were built on these basic concepts and became increas-
ingly sophisticated, including chimeric compounds, that embodied
different but established approaches. Today, the pipeline of potential
radiosensitizers contains compounds with diverse functionalities and
equally diverse sources, including the agrochemical and aerospace in-
dustry, as well as natural and biologically targeted products.
With more than 60% of cancer patients receiving radiotherapy at
some period in the natural history of their diseases, there has been a
recent focus on the development of molecular targeted compounds
that show preclinical promise as radiosensitizers and as chemosensi-
tizers. Before this, existing drugs with radiosensitizing properties (e.g.,
platinum analogs) were not widely used for their sensitizing effects,
in part, because of the risk of enhancing radiation damage to normal
tissues.
The six degrees of separation that we have applied to radiosensitizers
to explain their connectedness to oxygen and to each other can also be
used to account for their relatively neglected clinical status. Overgaard,
in a recent review on radiosensitizers [126], lamented that despite in-
tense preclinical interest, radiosensitizers were all but ignored in routine
clinical practice. He attributed this clinical apathy to lack of commercial
support for an area with a poor track record for the identification and
development of new compounds. In a sense, the problem is that radio-
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sensitizers are too connected: If compounds that are representative of a
class of treatment repeatedly fail clinically, the perception of commer-
cial and clinical viability of interconnected approaches is affected. For
example, interest in hypoxic radiosensitizers has waned because of the
continued failure of the nitroimidazoles and of tirapazamine itself.
Moreover, the lack of benefit of increased O2 delivery approaches un-
dermined not only the oxygen sensitization branch area as a whole but
also because of oxygen’s centrality, the entire field of radiosensitization
was adversely affected. However, there remains a large unmet medical
need to potentiate the effects of radiotherapy. In a similar way to ex-
ploiting the hypoxia phenomenon, the interconnectedness of radio-
sensitizers also represents a potential advantage, because clinical success
is more likely to rejuvenate this overlapping field compared to many
other therapeutic areas.
Nitric oxide represents a radical departure from other radiosensiti-
zers. As an endogenous compound, nitric oxide may equal or surpass
its molecular cousin, oxygen, as a hypoxic radiosensitizer, through
pleiotropic phenotypic effects on tumor perfusion, cell signaling, mito-
chondrial respiration, the fixation of radiation-induced damage, and the
radioprotection of normal tissue. However, unlike oxygen, in the con-
text of radiosensitization, the clinical role and utility of NO is poorly
understood, with often contradictory and controversial reported effects.
Whether nitric oxide functions as a radiosensitizer may ultimately be
contextual to the tumor microenvironment, depending on the architec-
ture of the vasculature, the presence or absence of smooth muscle cov-
erage, hypoxic status, thrombospondin 1/CD47 concentration and
expression, and the effect of NO on angiogenesis. This may make
NO manipulation an ideal candidate for a personalized radio-
sensitization approach tailored to specific patient and tumor types/
microenvironmental characteristics. Effective delivery of nitric oxide
both systemically and directly to the tumor may be critical to the suc-
cess of this approach. Compounds that release nitric oxide or nitric
oxide precursors have the potential to drive innovation and result in
a new fertile branch of the radiosensitizer tree.
Using the six degrees of separation for radiosensitizers, all of which
are descended from the common ancestor oxygen, it is possible to tran-
scend the traditional boundaries of chemical structure and compound
class. This way, all the compounds in the phylogenetic tree can be
evaluated as a related group in the context of the oxygen effect. This
knowledge can be then used in the design of new radiosensitizers and
combination therapies.
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